Hepatic-arterial infusion of the monoclonal antibodies cetuximab and bevacizumab results in a significant reduction of tumor growth of colorectal liver metastases

Authors :: Sperling, J
Brandhorst, D
Benz, A
Ziemann, C
Kollmar, O
Schilling, MK
Menger, MD
Source :: 128. Kongress der Deutschen Gesellschaft für Chirurgie; 20110503-20110506; München; DOC11dgch353 /20110520/
Publication Year :: 2011
Publisher :: German Medical Science GMS Publishing House, 2011.
Abstract: Introduction: Systemic chemotherapy (SYS) remains the gold standard in the treatment of irresectable colorectal liver metastases. The addition of the monoclonal antibodies (mAb) cetuximab or bevacizumab has led to further improvement of outcome. However, a hepatic-arterial infusion (HAI) as locoregional[for full text, please go to the a.m. URL]<br />128. Kongress der Deutschen Gesellschaft für Chirurgie

Language :: English
Database :: OpenAIRE
Journal :: 128. Kongress der Deutschen Gesellschaft für Chirurgie; 20110503-20110506; München; DOC11dgch353 /20110520/
Accession number :: edsair.doi.dedup.....29f51f8073d2e2cf479439d7f9d5fcce
Full Text :: https://doi.org/10.3205/11dgch353

Full Text Access

Tools